Business
Oxford BioMedica Wins Significant Funding
Oxford BioMedica Wins Significant Funding.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 7488N Oxford Biomedica PLC 11 September 2013 \n\n \n \n \n \n \n \nOxford BioMedica Wins Significant Funding via a Competitive Award from UK Government's Advanced Manufacturing Supply Chain Initiative\n \n-- UK consortium wins £7.7 million total funding, of which £7.1 million awarded to Oxford BioMedica as lead member --\n \n-- Funding to support the development of a centre of excellence in Oxford for specialist manufacture of gene-based therapies and to help create world-class excellence in supply chains --\n \nOxford, UK - 11 September 2013: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE: OXB), the leading gene-based biopharmaceutical company, announces that it has been selected as a winner of a funding award under the UK Government's Advanced Manufacturing Supply Chain Initiative (AMSCI), in recognition of the Company's potential to become a world-leader in Advanced Therapy Medicinal Product (ATMP) manufacture and supply chain expertise. \n \nThe winning innovative projects in established UK advanced manufacturing sectors were announced today at the Government's Industrial Strategy Conference at Warwick University. AMSCI was established to help existing UK supply chains grow and achieve world-class standards. \n \nOxford BioMedica led the successful bid with four other UK-based participants: the Heart of England NHS Foundation, Cranfield University, Cell Therapy Catapult Ltd and Biotec Services International Ltd (together, the \"consortium\"). Subject to due diligence and final confirmation by Birmingham City Council, the consortium has been awarded a £2.4 million grant, of which Oxford BioMedica will receive £1.8 million, and a £5.3 million loan to Oxford BioMedica which is repayable by March 2017.\n \nThe winning project\nBuilding on recent UK Government initiatives to support the life sciences sector, the £7.7 million total funding award will support the development of a centre of excellence in ATMP supply chains in the UK with a focus on gene-based therapies at Oxford BioMedica. In particular, over the next two years the Company, supported by the consortium, will develop its capability in serum-free, non-adherent manufacturing techniques and expand its proprietary manufacturing facility in...